|
gptkbp:instance_of
|
gptkb:botulism
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Xeomin
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
cosmetic procedures
therapeutic procedures
|
|
gptkbp:contraindication
|
infection at injection site
allergy to botulinum toxin
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:drug_interactions
|
antibiotics
anticoagulants
muscle relaxants
aminoglycosides
|
|
gptkbp:duration
|
3 to 6 months
|
|
gptkbp:effective_date
|
gptkb:2010
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xeomin
|
|
gptkbp:indication
|
spasticity
chronic migraine
hyperhidrosis
overactive bladder
|
|
gptkbp:ingredients
|
gptkb:incobotulinumtoxin_A
|
|
gptkbp:invention
|
gptkb:2022
|
|
gptkbp:manufacturer
|
gptkb:Medytox
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibition of acetylcholine release
|
|
gptkbp:patient_education
|
report any severe side effects
avoid rubbing injection site
follow-up appointments recommended
|
|
gptkbp:pharmacokinetics
|
local diffusion
neuromuscular blockade
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Society_of_Plastic_Surgeons
gptkb:American_Academy_of_Neurology
|
|
gptkbp:recommissioned
|
with saline solution
|
|
gptkbp:related_to
|
gptkb:Botox
gptkb:Dysport
|
|
gptkbp:route_of_administration
|
injection
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
swelling
vision problems
muscle weakness
difficulty swallowing
dry mouth
pain at injection site
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
treatment of blepharospasm
treatment of cervical dystonia
treatment of wrinkles
|
|
gptkbp:bfsParent
|
gptkb:Botox
|
|
gptkbp:bfsLayer
|
6
|